Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Applauds U.K.'s Tax Changes, Announces New Jobs And Manufacturing Facilities

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline is to invest £500 million in new U.K. manufacturing facilities in Ulverston, Montrose and Irvine, creating 1,000 jobs in the process.

You may also be interested in...



Patent Incentives Pitched As Part Of Corporate Tax Reform

European-style 'patent box' recommended by former Allergan CEO at Senate hearing.

European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box

EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.

Pfizer/AstraZeneca: Battleground Shifts To U.K. Parliament

Pfizer CEO Read tried to assure U.K. legislators that an acquisition of the country’s second-largest drug company would not stunt pharma R&D in Britain at a May 13hearing. AstraZeneca CEO Soriot countered that the company’s pipeline will progress quicker if the company remains independent, resulting in future benefits to the U.K.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel